source
- Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialInhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.BioPharma Dive · 2mo ago↗ source
- Biotech layoffs are easing, but is the worst over?BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.BioPharma Dive · 2mo ago↗ source
- Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 2mo ago↗ source